Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
What biologic treatment – if any – is currently available for nonallergic asthma patients?
Paul O’Byrne:
Nonallergic asthma is often eosinophilic. In fact, in the initial studies done with the anti-interleukin (IL)-5 biologics, many of these patients were not allergic, at least as measured by either positive skin tests or elevated levels of IgE. Having nonallergic asthma certainly does not eliminate the potential benefit of anti-IL-5 monoclonals – particularly, of course, if they have a persistent airway eosinophilia.
See also
Asthma and ICSs in patients with chronic cough
Asthma is thought to be one of the most common causes of chronic cough. After some basic diagnostic workup, is it reasonable to start a trial of inhaled corticosteroids in most patients? Or should each patient with suspected asthma undergo a bronchial provocation test or another specialist test?
Simplified criteria in lung cancer screening programs
Some current lung cancer screening programs have simplified inclusion criteria, limited to age over 55 years and significant exposure to tobacco smoke. Do you think such criteria are appropriate?
Role of COPD phenotypes in treatment
Is it likely that in the near future the knowledge on chronic obstructive pulmonary disease (COPD) phenotypes will help to choose an optimal treatment?
Sedation in patients on noninvasive ventilation
What is your opinion on sedation of patients on noninvasive ventilation? In BTS guidelines, sedation with morphine is an optional approach in agitated patients receiving NIV.
Asthma–COPD overlap syndrome
A lecture by Prof. Paul O’Byrne, from McMaster University, Canada, delivered at McMaster International Review Course in Internal Medicine in Kraków in May 2016.
English
Polski
Español
українська
